The company expects first quarter 2025 revenue to be in the range of $100 million to $120 million and first quarter 2025 EPS to range from a loss of $0.50 per diluted share to $0.00 per diluted share. The EPS range excludes any gains or losses from changes in market price of the company’s LifeMD common stock investment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MED:
Questions or Comments about the article? Write to editor@tipranks.com